AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1831686 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with three-monthly scale and polish (Group 3)
Number of subjects: 382
Study 7159690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet containing 25 mg bemetizide and 50 mg triamterene
Number of subjects: 0
Study 7159690 — intervention group
Group type: COMPARATOR
Intervention: Bemetizide alone (25 mg)
Number of subjects: 0
Study 7159690 — intervention group
Group type: COMPARATOR
Intervention: Triamterene alone (50 mg)
Number of subjects: 0
Study 31033867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 2,400 mg per day
Number of subjects: 42
Study 31033867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 1,500 mg per day
Number of subjects: 42
Study 31033867 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted sodium intake (control group)
Number of subjects: 42
Study 26485692 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Method (FM)
Number of subjects: 105
Study 26485692 — intervention group
Group type: COMPARATOR
Intervention: Hand Method (HM)
Number of subjects: 105
Study 26010521 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mg transdermal nicotine patch
Number of subjects: 32
Study 26010521 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 32
Study 26010521 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Number of subjects: 32
Study 26010521 — intervention group
Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 32
Study 23250992 — intervention group
Group type: EXPERIMENTAL
Intervention: CR orientation appointment within 10 days (early)
Number of subjects: 148
Study 23250992 — intervention group
Group type: COMPARATOR
Intervention: CR orientation appointment at 35 days (standard)
Number of subjects: 148
Study 22015074 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (30-minute intravenous infusion)
Number of subjects: 8
Study 22015074 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 8
Study 18091545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with meropenem (1 g every 8 hrs) and ciprofloxacin (400 mg every 12 hrs)
Number of subjects: 740
Study 18091545 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with meropenem alone
Number of subjects: 740
Study 18091545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 740
Study 18091545 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 740
Study 17146023 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills-oriented physical activity intervention in physical education class
Number of subjects: 221
Study 17146023 — intervention group
Group type: COMPARATOR
Intervention: Standard physical education class (control)
Number of subjects: 221
Study 17146023 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills-oriented physical activity intervention
Number of subjects: 221
Study 17146023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study 15019339 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery performed by ophthalmologists
Number of subjects: 982
Study 15019339 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery performed by integrated eye care workers (IECWs)
Number of subjects: 982
Study 15019339 — intervention group
Group type: COMPARATOR
Intervention: Overall recurrence
Number of subjects: 982
Study 11320045 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamsylate
Number of subjects: 334
Study 11320045 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study 9203645 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 554
Study 9203645 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 554
Study 8203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CP; 2.0 g IV every 12 h)
Number of subjects: 133
Study 8203833 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (CZ; 2.0 g IV every 8 h)
Number of subjects: 133
Study 8203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CP)
Number of subjects: 133
Study 8203833 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (CZ)
Number of subjects: 133
Study 3295623 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm 1
Number of subjects: 188
Study 3295623 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm 2
Number of subjects: 188
Study 3295623 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study 31863557 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1450 ± 550 mg/day)
Number of subjects: 36
Study 31863557 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 36
Study 31863557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29962867 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered metallic ureteral stent (CMS)
Number of subjects: 19
Study 29962867 — intervention group
Group type: COMPARATOR
Intervention: Double-J ureteral stent (DJS)
Number of subjects: 19
Study 27631145 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive collaborative care for depression
Number of subjects: 190
Study 24237962 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of combined endurance and strength training (4 sessions per week)
Number of subjects: 26
Study 24237962 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute endurance workload of 45 min at 70% of VO(2max)
Number of subjects: 26
Study 24237962 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of combined endurance and strength training
Number of subjects: 26
Study 24237962 — intervention group
Group type: COMPARATOR
Intervention: Pre-diabetes subjects
Number of subjects: 26
Study 22579509 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (positive) computer-based attentional bias modification (ABM) with face-based stimuli
Number of subjects: 61
Study 22579509 — intervention group
Group type: COMPARATOR
Intervention: Placebo computer-based attentional bias modification (ABM) with word-based stimuli
Number of subjects: 61
Study 19889408 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (16 hours)
Number of subjects: 36
Study 19889408 — intervention group
Group type: COMPARATOR
Intervention: Patient-based training (control)
Number of subjects: 36
Study 18188742 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Pack Program (moderately intensive, E-mail-based intervention)
Number of subjects: 83
Study 18188742 — intervention group
Group type: COMPARATOR
Intervention: Clearing the Air group (less-intensive program aimed at a general adult audience)
Number of subjects: 83
Study 16489197 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvex plastic mask system
Number of subjects: 20
Study 16489197 — intervention group
Group type: COMPARATOR
Intervention: Finesse Frame with Ultraplast System
Number of subjects: 20
Study 12785418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 180
Study 12785418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to speak English
Number of subjects: 180
Study 12785418 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of health insurance
Number of subjects: 180
Study 12785418 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of mammography
Number of subjects: 180
Study 10752582 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Inverted Stick (MIS)
Number of subjects: 28
Study 10752582 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Laser Beam Stick (LBS)
Number of subjects: 28
Study 10752582 — intervention group
Group type: COMPARATOR
Intervention: Unassisted Walking (UW)
Number of subjects: 28
Study 9411698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital block
Number of subjects: 51
Study 1396725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg t.i.d. followed by oral cefuroxime axetil 500 mg b.i.d.
Number of subjects: 512
Study 1396725 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin plus clavulanic acid (1.2 g intravenously t.i.d. followed by 625 mg orally t.i.d.)
Number of subjects: 512
Study 1396725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime/cefuroxime axetil
Number of subjects: 512
Study 1396725 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/CA
Number of subjects: 512
Study 1396725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime regimen
Number of subjects: 512
Study 3091097 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day methylene blue
Number of subjects: 31
Study 3091097 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/day methylene blue (control)
Number of subjects: 31
Study 30532527 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 µg/day
Number of subjects: 141
Study 30532527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 27884204 — intervention group
Group type: EXPERIMENTAL
Intervention: TME + LLND
Number of subjects: 512
Study 27884204 — intervention group
Group type: COMPARATOR
Intervention: TME
Number of subjects: 512
Study 24277915 — intervention group
Group type: EXPERIMENTAL
Intervention: Silirum vaccine
Number of subjects: 3335
Study 24277915 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaccination)
Number of subjects: 3335
Study 22176900 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinzhihuang oral liquid combined with phototherapy
Number of subjects: 1177
Study 22176900 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital combined with phototherapy
Number of subjects: 1177
Study 22176900 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 1177
Study 18831071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (PASCET-PI)
Number of subjects: 41
Study 18831071 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 41
Study 17571600 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (M group) administered continuously at a rate of 0.15‐0.30 microg x kg(‐1) min(‐1) after sternotomy until the end of operation.
Number of subjects: 30
Study 17571600 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group) received saline.
Number of subjects: 30
Study 15257113 — intervention group
Group type: EXPERIMENTAL
Intervention: GES ON
Number of subjects: 9
Study 15257113 — intervention group
Group type: EXPERIMENTAL
Intervention: GES OFF
Number of subjects: 9
Study 15257113 — intervention group
Group type: COMPARATOR
Intervention: Medication NR
Number of subjects: 9
Study 15257113 — intervention group
Group type: COMPARATOR
Intervention: Medication RES
Number of subjects: 9
Study 15257113 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 9
Study 11448916 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic therapy with razoxane
Number of subjects: 43
Study 9699660 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT rapid acetylation genotype
Number of subjects: 433
Study 9699660 — intervention group
Group type: COMPARATOR
Intervention: NAT1 rapid acetylation genotype
Number of subjects: 433
Study 9699660 — intervention group
Group type: COMPARATOR
Intervention: NAT2 rapid acetylation genotype
Number of subjects: 433
Study 9699660 — intervention group
Group type: COMPARATOR
Intervention: NAT1/NAT2 combined rapid acetylation genotype
Number of subjects: 433
Study 8064281 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with radiation therapy
Number of subjects: 86
Study 8064281 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (Control)
Number of subjects: 86
Study 8064281 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (both groups)
Number of subjects: 86
Study 2729484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot/Ice Thermal Blanket
Number of subjects: 54
Study 2729484 — intervention group
Group type: COMPARATOR
Intervention: Control (no Hot/Ice unit)
Number of subjects: 54
Study 4951240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl intramuscularly
Number of subjects: 75
Study 4951240 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine intramuscularly
Number of subjects: 75
Study 4951240 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl
Number of subjects: 75
Study 4951240 — intervention group
Group type: COMPARATOR
Intervention: morphine
Number of subjects: 75
Study 30489494 — intervention group
Group type: COMPARATOR
Intervention: Evening Training (ET)
Number of subjects: 50
Study 30489494 — intervention group
Group type: COMPARATOR
Intervention: Morning Training (MT)
Number of subjects: 50
Study 30489494 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 50
Study 27171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (monotherapy)
Number of subjects: 506
Study 27171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (add-on to metformin)
Number of subjects: 506
Study 27171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (add-on to pioglitazone)
Number of subjects: 506
Study 27171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (any treatment group)
Number of subjects: 506
Study 27171508 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin and placebo
Number of subjects: 506
Study 27171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 506
Study 27171508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 25511300 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial toothpaste (1100 ppm F, pH7.0 and conventional viscosity)
Number of subjects: 19
Study 25511300 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD) (1100 ppm F, pH7.0 and low viscosity)
Number of subjects: 19
Study 25511300 — intervention group
Group type: EXPERIMENTAL
Intervention: ELD (1100 ppm F and high viscosity pH7.0)
Number of subjects: 19
Study 25511300 — intervention group
Group type: COMPARATOR
Intervention: NaF solution at pH4.5
Number of subjects: 19
Study 25511300 — intervention group
Group type: COMPARATOR
Intervention: NaF solution at pH7.0
Number of subjects: 19
Study 25511300 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing
Number of subjects: 19
Study 23586654 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1234
Study 23586654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1234
Study 22069045 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b plus lamivudine 100 mg/d
Number of subjects: 59
Study 22069045 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFNα‐2b 1.5 µg/kg o. i. w.
Number of subjects: 59
Study 19906442 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 74
Study 19906442 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic psychotherapy
Number of subjects: 74
Study 22151600 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence (top two quintiles)
Number of subjects: 34827
Study 15795477 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (45 min exercise at 70% VO2max, 4 times in the first week and 3 times in the next 2 weeks)
Number of subjects: 12
Study 12196081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg, once daily, starting 6 hours after surgery)
Number of subjects: 7344
Study 12196081 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (approved regimens)
Number of subjects: 7344
Study 12196081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 7344
Study 12196081 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux and Enoxaparin
Number of subjects: 7344
Study 9706946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.25 mg/kg
Number of subjects: 60
Study 9706946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.15 mg/kg
Number of subjects: 60
Study 9706946 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium 0.15 mg/kg
Number of subjects: 60
Study 7888933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian advice
Number of subjects: 309
Study 7888933 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurse advice
Number of subjects: 309
Study 7888933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet leaflet
Number of subjects: 309
Study 7888933 — intervention group
Group type: COMPARATOR
Intervention: All groups pooled
Number of subjects: 309
Study 2404050 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of sodium intake
Number of subjects: 0
Study 2404050 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of potassium intake
Number of subjects: 0
Study 2404050 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of energy intake
Number of subjects: 0
Study 2404050 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 389838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 25 mg/day)
Number of subjects: 0
Study 389838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined indomethacin + sodium-salicylate (3 x 25 mg/day and 3 x 250 mg/day)
Number of subjects: 0
Study 30203300 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma film exposure
Number of subjects: 95
Study 30203300 — intervention group
Group type: COMPARATOR
Intervention: Neutral film exposure
Number of subjects: 95
Study 30203300 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma film exposure in males
Number of subjects: 95
Study 30203300 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance response in males
Number of subjects: 95
Study 27796072 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-/CAM-produced monolithic LS2-crowns bonded to prefabricated titanium abutments without any physical models (test)
Number of subjects: 20
Study 27796072 — intervention group
Group type: COMPARATOR
Intervention: CAD-/CAM-fabricated ZrO2-suprastructures and hand-layered ceramic veneering with milled master models (control)
Number of subjects: 20
Study 27796072 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete digital workflow for test
Number of subjects: 20
Study 27796072 — intervention group
Group type: COMPARATOR
Intervention: Complete digital workflow for control
Number of subjects: 20
Study 27796072 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory work time for test
Number of subjects: 20
Study 27796072 — intervention group
Group type: COMPARATOR
Intervention: Laboratory work time for control
Number of subjects: 20
Study 25596420 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 216
Study 25596420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 24343683 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) with a protocol consisting of 10 stages, including breathing exercises, resistance training, stretching, and walking.
Number of subjects: 22
Study 24343683 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with routine exercise program.
Number of subjects: 22
Study 24343683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 22
Study 19830413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pummelo juice with 50 mg sildenafil
Number of subjects: 6
Study 19830413 — intervention group
Group type: COMPARATOR
Intervention: Water with 50 mg sildenafil
Number of subjects: 6
Study 17991471 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha at 1.5 microg/kg every 20 days plus iron orally (n=21)
Number of subjects: 41
Study 17991471 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus iron orally (n=20)
Number of subjects: 41
Study 16191447 — intervention group
Group type: EXPERIMENTAL
Intervention: Canary
Number of subjects: 144
Study 16191447 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant
Number of subjects: 144
Study 16191447 — intervention group
Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 144
Study 14763193 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of quinacrine at each cornual angle (3 double insertions, a month apart)
Number of subjects: 1997
Study 14763193 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of quinacrine at each cornual angle (single double insertion)
Number of subjects: 1997
Study 14763193 — intervention group
Group type: EXPERIMENTAL
Intervention: 252 mg to 360 mg of quinacrine (2 insertions, a month apart, fundal placement)
Number of subjects: 1997
Study 11030470 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide 120 mg 3 times daily before meals
Number of subjects: 0
Study 11030470 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide 120 mg plus metformin 500 mg, both 3 times daily
Number of subjects: 0
Study 11030470 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide 60 or 120 mg 3 times daily plus metformin 1 g twice daily
Number of subjects: 0
Study 11030470 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide 120 mg 3 times daily
Number of subjects: 0
Study 11030470 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with troglitazone 600 mg daily
Number of subjects: 0
Study 8654613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and periaortic peritoneal closure (group I, n = 50)
Number of subjects: 102
Study 8654613 — intervention group
Group type: COMPARATOR
Intervention: Peritoneum non-closure (group II, n = 52)
Number of subjects: 102
Study 8654613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 102
Study 8654613 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients after chemotherapy
Number of subjects: 102
Study 1794820 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival application of 20 micrograms adrenaline in both eyes
Number of subjects: 40
Study 1794820 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 100 micrograms adrenaline into the anterior chamber
Number of subjects: 40
Study 1794820 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (controls) in the anterior chamber
Number of subjects: 40
Study 1794820 — intervention group
Group type: COMPARATOR
Intervention: No adrenaline (controls) for strabismus surgery
Number of subjects: 40